Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Limited-stage small-cell lung cancer, drawn from the whole corpus: 10 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Whether prophylactic cranial irradiation still helps when MRI surveillance is available is being tested in randomised trials.
The best radiotherapy dose and schedule to combine with immunotherapy is unknown.
Most patients still relapse after chemoradiation and durvalumab, and there is no biomarker for who will be cured.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Treatment journeys · Survivorship planner.
Transformed small-cell disease arising from EGFR-mutated adenocarcinoma is treated as limited or extensive stage without evidence specific to it.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 9 changes by month →When this page itself was last checked or edited.
OS HR 0.
OS 55.
A milestone in how this cancer is treated.
No significant difference; twice-daily 45 Gy remains standard.
A milestone in how this cancer is treated.